Prostate Cancer Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

Metastatic Prostate Cancer

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Description: The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

Investigators

Eligibility Requirements

Male subjects 18 y/o and older with a clinical diagnosis of metastatic prostate cancer

Status

Active and open to enrollment

Contacts

Joni Beemsterboer, 415-600-3967

Non-Metastatic Prostate Cancer

 

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Description: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Male subjects 18 y/o and older with a pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence

Status

Please contact site for study status

Contacts

Joni Beemsterboer, 415-600-3967